CVS HEALTH Corp (CVS) stock intrinsic value fair value estimate & owner earnings analysis

CVS Health runs three linked businesses: Caremark, one of the three largest pharmacy benefit managers in the United States; Aetna, a health insurer with a large Medicare Advantage book; and the CVS Pharmacy retail chain. Revenue reached $402 billion in 2025, but margins are thin, so small changes in medical cost trends, drug reimbursement or PBM rules move profits a lot. How we measured earnings. We start from operating cash flow and remove working-capital swings, stock-based pay and the capital spending needed to keep the business running. Per diluted share this came to $6.47 (2019), $7.59 (2020), $8.74 (2021), $4.89 (2022), $7.84 (2023), $4.61 (2024) and $7.09 (2025). Adding back roughly $3 billion a year of interest gives the cash the whole business produces before paying lenders: $8.73, $9.80, $10.60, $6.58, $9.72, $6.91 and $9.45 per share. We use the median of 2019 through 2025, $9.45, because the Aetna purchase at the end of 2018 created today's company. The window includes the pandemic boost of 2021, the 2022 opioid settlement charge and the 2024 Medicare Advantage cost spike, and dropping those three years would move the median only slightly, from $9.45 to $9.59. About $2 billion a year of amortization on acquired intangibles (mostly Aetna's customer relationships) is added back. Those franchises are renewed through ordinary selling and service costs that are already deducted, and we hold earnings flat in dollars rather than letting them grow, which allows for their erosion after inflation. The $5.7 billion Omnicare goodwill write-off in 2025 was also added back, but CVS has written down its long-term-care purchase twice ($6.1 billion in 2018 and again in 2025), and that record weighs on the bear case. Recent results. In 2025, owner earnings per share rose 54% and cash flow before interest rose 37%, even after $919 million of one-time loss provisions on the individual exchange and group Medicare Advantage books. Aetna's medical benefit ratio improved to 91.2% from 92.5%, though it is still well above the mid-80s level of earlier years. In the first half of 2026, net income was $5.95 billion against $2.80 billion a year earlier, and operating cash flow was $10.6 billion against $6.5 billion. Because Aetna's earnings are seasonally weaker late in the year, our base case uses $10.00 per share for the first year, 6% above the anchor and far below last year's 37% gain. What it owes. At June 30, 2026, borrowings including finance leases were $61.4 billion. We add $4.5 billion of settled or adjudicated litigation, mainly the remaining $4.0 billion opioid settlement accrual, plus a $291 million Medicare Part D False Claims Act judgment that CVS is appealing and $165 million of Omnicare-related liability. We also add $0.2 billion of outside ownership in subsidiaries. We subtract $2.8 billion of cash held outside the regulated insurance subsidiaries. Much of the debt is long-dated fixed-rate paper costing about 5%, below our 6% yardstick; that cheaper financing is worth about $4.1 billion, which we deduct from what is owed. Net debt is about $59.2 billion, or $45.97 per share. No near-term maturity is large: $2.0 billion is due within a year, against about $3 billion of annual interest. Base case ($116.77). Cash flow before interest is $10.00 per share next year, then $9.75 a year with no growth, which is between the multi-year median and the 2026 run rate. We give no credit for an aging population, GLP-1 drug volume, Medicare Advantage margins returning to their old levels or new clinic growth, because none of these is secured. What keeps earnings going beyond ten years is scale that has already lasted for decades: Caremark's purchasing position, Aetna's provider networks and customer base, and the retail pharmacy footprint. We hold the base flat in dollars instead of growing it. The business is worth about $162.74 per share ($209 billion). After $45.97 of net debt, the shares are worth $116.77. Bear case ($27.34). This case builds on risks that are already on the record. The FTC's 2024 insulin-rebating complaint against the three largest PBMs, ongoing federal and state investigations, and state laws in Arkansas, Louisiana, North Dakota and Oklahoma aimed at PBM practices all point toward lower Caremark economics. Aetna also stays stuck near its 2024 cost levels. Cash flow falls from $9.00 to $7.50 and then to $6.50 per share through year ten, slightly below the 2022 and 2024 trough years. It then fades to zero over the following twenty years as the PBM and retail models erode, and we charge another $1.50 per share for opioid and False Claims Act cases still pending, including the Department of Justice suit filed in December 2024. The business is worth $73.31 per share ($94 billion) against $45.97 of debt, leaving $27.34. Even here the business earns about $8.4 billion a year before interest, more than enough to pay its lenders. Bull case ($144.31). Aetna's repricing and benefit changes, already showing in the 2025 and first-half 2026 results, keep working, and the 2026 earnings rate holds. Cash flow is $10.50 and then $11.00, then levels off at $11.50 per share, roughly CVS's best post-Aetna years, with no growth after that. The business is worth $190.28 per share ($245 billion). After debt, the shares are worth $144.31. What would make this wrong. Federal legislation that restricts PBMs' retained rebates or forces them to separate from their pharmacies could cut Caremark's profit faster than the bear case assumes. Medicare Advantage payment rates or risk-adjustment changes could keep Aetna's margins at 2024 levels. On the other side, further medical cost improvement would push results toward the bull case. The per-share figures assume today's roughly 1.29 billion diluted shares, since buybacks were halted in 2025.